UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over claims that a discontinued version of its heartburn drug Zantac caused cancer.

GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer.

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug. GSK suffered ...

Tens of thousands of Americans are in line to share $2.2bn (£1.7bn) after GSK agreed a settlement over claims its indigestion drug caused cancers. The British drug giant has agreed to pay up to $ ...

The British drugmaker’s settlement with 10 separate law firms resolves 93% of all U.S. cases currently filed against GSK over claims its popular Zantac drug contained the carcinogen N ...

The first lawsuit claiming that gastrointestinal drug Zantac causes cancer has been voluntarily dismissed a week before it was due to come to trial, in an early victory for the pharma companies ...

A hearing will get underway in Delaware later today in the latest phase of GSK’s attempts to defend itself from allegations that its Zantac drug caused cancer in patients. The three-day hearing ...

The central repository of the drug and medication centre helps to navigate to different sections. Medindia's platform provides carefully curated details on generics, brand names, side-effects ...

ranitidine, turned into the potential carcinogen NDMA under certain conditions. The US Food and Drug Administration asked companies producing Zantac to remove all ranitidine-based drugs from the U ...

Tens of thousands of Americans are in line to share $2.2bn (£1.7bn) after GSK agreed a settlement over claims its indigestion drug caused cancers. The British drug giant has agreed to pay up to $2.2bn ...